Dimensional Fund Advisors LP Sells 11,668 Shares of Avanos Medical, Inc. (NYSE:AVNS)

Dimensional Fund Advisors LP trimmed its holdings in Avanos Medical, Inc. (NYSE:AVNS) by 0.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,578,317 shares of the company’s stock after selling 11,668 shares during the period. Dimensional Fund Advisors LP owned about 5.61% of Avanos Medical worth $41,046,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Quantbot Technologies LP bought a new position in Avanos Medical in the 4th quarter valued at about $64,000. KLP Kapitalforvaltning AS bought a new position in shares of Avanos Medical in the fourth quarter valued at approximately $162,000. Mariner LLC boosted its position in shares of Avanos Medical by 18.0% during the fourth quarter. Mariner LLC now owns 10,655 shares of the company’s stock valued at $170,000 after buying an additional 1,625 shares during the last quarter. US Bancorp DE grew its holdings in Avanos Medical by 18.0% during the fourth quarter. US Bancorp DE now owns 14,093 shares of the company’s stock worth $224,000 after buying an additional 2,147 shares in the last quarter. Finally, Pitcairn Co. raised its position in Avanos Medical by 13.6% in the 4th quarter. Pitcairn Co. now owns 17,290 shares of the company’s stock valued at $275,000 after buying an additional 2,074 shares during the last quarter. 95.17% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, StockNews.com raised shares of Avanos Medical from a “hold” rating to a “buy” rating in a report on Wednesday, March 19th.

Insider Activity

In other news, SVP Kerr Holbrook sold 7,000 shares of the company’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $15.25, for a total transaction of $106,750.00. Following the transaction, the senior vice president now owns 82,047 shares of the company’s stock, valued at $1,251,216.75. This represents a 7.86 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.64% of the company’s stock.

Avanos Medical Price Performance

Shares of NYSE AVNS opened at $12.28 on Friday. The company has a market capitalization of $564.92 million, a PE ratio of 36.12 and a beta of 1.13. The company has a quick ratio of 1.46, a current ratio of 2.22 and a debt-to-equity ratio of 0.12. The stock’s 50 day moving average price is $13.69 and its 200-day moving average price is $16.39. Avanos Medical, Inc. has a twelve month low of $11.84 and a twelve month high of $25.36.

Avanos Medical (NYSE:AVNS) last posted its quarterly earnings data on Wednesday, February 26th. The company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.40 by $0.03. The business had revenue of $179.60 million for the quarter, compared to analysts’ expectations of $177.23 million. Avanos Medical had a return on equity of 4.70% and a net margin of 2.30%. On average, equities analysts anticipate that Avanos Medical, Inc. will post 1.32 EPS for the current year.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.